A Phase 3 interventional study of AD + SHR + active LT and extended-release melatonin 2mg and AD + SHR + active LT and placebo melatonin in Major Depressive Disorder (MDD) With Insomnia, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.
Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 57th largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2026, is one of 36 in phase 3, reaches primary completion later than 23 of the 30 other live ones, and was the 120th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–54 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 184 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 232 across the 106 interventional studies, 128 across the 21 observational. Of the 84 that completed or were terminated, 31 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 127 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 7 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
8 of the studies in Depressive Disorder, Major with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT06234176Centre Hospitalier EsquirolImpact of Psychomotor Therapy on the Quality of Life in Depression | 2027-02 |
| NCT06601140EmobotEvaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode | 2027-02-04 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 127 studies in Depressive Disorder, Major with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8 weeks of treatment. Insomnia, present in approximately 85% of individuals with MDD, is a frequent and persistent symptom that contributes to poor treatment outcomes. Targeting insomnia has been shown to enhance both symptom remission and functional recovery. In this context, combined therapeutic strategies are often used to optimize the antidepressant response. Among them, chronotherapeutic approaches, such as light therapy and prolonged-release melatonin, have demonstrated rapid antidepressant effects and are beneficial in regulating sleep and circadian rhythms. Light therapy shows an efficacy comparable to antidepressants and, when used in combination with them, can double treatment effectiveness. Melatonin is also recommended in the management of depression-related insomnia. This multicenter, randomized, double-blind, placebo-controlled trial with a 2x2 factorial design aims to evaluate the efficacy of two chronotherapeutic interventions, 8 weeks of active light therapy and 2 mg of prolonged-release melatonin-administered alone or in combination, on depressive symptom reduction at 8 weeks in adult patients with MDD and comorbid insomnia. The primary outcome is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline to week 8. All participants will receive antidepressant treatment and sleep hygiene education. This study proposes a novel therapeutic strategy combining pharmacological and non-pharmacological interventions to address both depression and insomnia, with the goal of improving outcomes, especially for the 40% of patients who do not adequately respond to antidepressants alone.
Major Depressive Disorder (MDD) affects approximately 5% of the global population and represents the second leading cause of disability worldwide. Despite the availability of pharmacological treatments, particularly antidepressants, their efficacy remains limited: nearly 50 to 60% of patients do not respond adequately after 8 weeks of treatment. One of the most common and persistent symptoms in MDD is insomnia, which affects about 85% of patients and frequently persists even after partial improvement of mood symptoms. Insomnia is not only a residual symptom but also a marker of poor prognosis and treatment resistance. Addressing sleep disturbances directly has been shown to enhance both symptomatic and functional remission in depression, making it a promising target for intervention.
In clinical practice, combination strategies are increasingly employed to improve therapeutic response, particularly in patients who are only partially responsive to antidepressant medication. Among these strategies, chronotherapeutic interventions, such as light therapy and prolonged-release melatonin, offer a compelling approach. These treatments have demonstrated rapid antidepressant effects, with some studies reporting clinical improvements as early as the first week of treatment. Additionally, both interventions are known to positively influence sleep quality and circadian rhythm regulation, which are often disrupted in depressive disorders.
Light therapy (LT), in particular, has shown efficacy comparable to that of antidepressants and works by synchronizing the sleep-wake cycle. When used in combination with antidepressants, LT has been associated with significantly greater reductions in depressive symptoms than antidepressants alone. Similarly, prolonged-release melatonin has been recommended in the management of insomnia comorbid with depression, further supporting the rationale for combining these chronotherapeutic agents.
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed in a 2x2 factorial format. It aims to evaluate the efficacy of two chronotherapeutic interventions, active light therapy (10,000 lux) for 8 weeks and 2 mg prolonged-release melatonin for 8 weeks, administered alone or in combination, in improving depressive symptoms at 8 weeks. The trial will enroll adult patients diagnosed with moderate to severe MDD and comorbid insomnia. The primary objective is to assess the change in depressive symptom severity, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) score, from baseline to week 8.
All participants, regardless of group allocation, will receive standard antidepressant treatment and structured sleep hygiene counseling to ensure a consistent baseline of care. This approach reflects real-world practices and enhances the ecological validity of the trial. The study also incorporates objective and subjective measures of sleep and circadian rhythms to explore the broader impact of the interventions.
By evaluating the combined and individual effects of light therapy and melatonin alongside standard care, this study seeks to establish an innovative and comprehensive therapeutic model. The goal is to improve outcomes for individuals with MDD and insomnia, particularly the substantial proportion of patients, up to 40%, who do not achieve adequate response with antidepressants alone. This trial represents a significant step toward more personalized, effective, and integrated treatment strategies for depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving active light therapy (approx. 10,000 Lux) and prolonged-release melatonin 2 mg taken 1 hour before bedtime, in combination with sleep and hygiene rules (SHR) and antidepressant treatment (AD)
Procedure: AD + SHR + active LT and extended-release melatonin 2mg
Patients receiving active light therapy (approx. 10,000 Lux) and placebo melatonin, in combination with SHR and AD.
Procedure: AD + SHR + active LT and placebo melatonin
Patients receiving placebo light therapy (filtered to approx. \<10 Lux) and prolonged-release melatonin 2 mg taken 1 hour before bedtime, in combination with SHR and AD.
Procedure: AD + SHR + placebo LT and extended-release melatonin 2mg
Patients receiving placebo light therapy (filtered to approx. \<10 Lux) and placebo melatonin (control group), in combination with SHR and AD.
Procedure: AD + SHR + placebo LT and placebo melatonin
Patients will receive an SSRI antidepressant (e.g., Fluoxetine, Sertraline, Paroxetine, Escitalopram) or SNRI (e.g., Venlafaxine, Duloxetine) antidepressant (as clinically appropriate), combined with sleep hygiene education, daily morning LT (10,000 lux for 30 minutes between 7-8 a.m. using the Dayvia Slim Style 3 lamp), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily morning bright LT (10,000 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps in non-therapeutic mode), and 2 mg of extended-release melatonin taken one hour before bedtime, all for a duration of 8 weeks.
Patients will receive an SSRI or SNRI, sleep hygiene instructions, daily placebo light exposure (\<10 lux, 30 cm, 30 min, 7-8 a.m., using Dayvia Slim Style 3 lamps), and oral placebo melatonin taken one hour before bedtime, all for a duration of 8 weeks.
Assessment of the efficacy of two chronotherapeutics (LT and extended-release melatonin 2mg), alone or combined, associated to AD on depressive symptoms reduction after 8 weeks of treatment
Measure the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score between the inclusion visit (V0, S0) and Week 8 (V3, S8) in patients with moderate to severe major depressive episode and insomnia
Time frame: At baseline (Week 0) and at Week 8
Assessment of the efficacy of chronotherapeutics, combine or alone, on depressive symptoms evolution
Measure changes in MADRS scores from baseline (inclusion visit) to each follow-up visit (Week 1, Week 4, Week 8, and Month 3).
Time frame: Weeks 1, 4, 8, and Month 3
Determination of the rate of therapeutic response to chronotherapeutics at each follow-up visit
Proportion of patients achieving ≥50% reduction in MADRS score at each follow-up visit (Week 1, Week 4, Week 8 and Month 3) as compared to baseline (inclusion visit)
Time frame: Weeks 1, 4, 8, and Month 3
Determination of the rate of remission in depressive symptoms
Proportion of patients with MADRS score ≤10 at specified time points (Weeks 4, 8 and Month 3).
Time frame: Weeks 4, 8, and Month 3
Evaluation of the impact of chronotherapeutics on subjective sleep
Assessment using self-reported sleep questionnaires, sleep-wake rhythm diaries, and sleep logs
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of the impact of chronotherapeutics on circadian rhythm
Assessment using self-reported sleep questionnaires, sleep-wake rhythm diaries, and sleep logs
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of changes in objective sleep measured by actigraphy
Total sleep time
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective sleep measured by actigraphy
Wake After Sleep Onset (WASO)
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective sleep measured by actigraphy
Fragmentation index
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective sleep measured by actigraphy
Sleep efficiency
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective sleep measured by actigraphy
Time in bed
Time frame: Weeks 1, 4, and 8
Evaluation of changes in sleep rhythm parameters measured by actigraphy
Total Sleep Time
Time frame: Weeks 1, 4, and 8
Evaluation of changes in sleep rhythm parameters measured by actigraphy
Wake After Sleep Onset (WASO)
Time frame: Weeks 1, 4, and 8
Evaluation of changes in sleep rhythm parameters measured by actigraphy
Fragmentation Index
Time frame: Weeks 1, 4, and 8
Evaluation of changes in sleep rhythm parameters measured by actigraphy
Sleep Efficiency
Time frame: Weeks 1, 4, and 8
Evaluation of changes in sleep rhythm parameters measured by actigraphy
Time in Bed
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters
Relative amplitude
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters
Interdaily stability/variability
Time frame: Weeks 1, 4, and 8
Evaluation of changes in objective actigraphy-derived sleep and rhythm parameters
L5/M10 onset markers
Time frame: Weeks 1, 4, and 8
Modeling of the longitudinal trajectory of MADRS scores
Analyze the slope of MADRS score changes across visits to characterize symptom progression or improvement.
Time frame: From baseline to Week 8 and from baseline to Month 3
Measurement of time to therapeutic response
Time (in days) from inclusion to achievement of ≥50% reduction in MADRS score.
Time frame: From baseline to Month 3
Evaluation of the tolerability of chronotherapeutic combinations
Evaluate adverse events using the PRISE-M side effects questionnaire.
Time frame: Weeks 1, 4, and 8
Evaluation of mood state
Scores on YMRS (mania)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of mood state
C-SSRS (suicidal ideation)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of mood state
QIDS-SR (depression)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of mood state
GAD-7 (anxiety)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of mood state
CGI (clinical global impression)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of global functioning evolution
Scores on YMRS (mania)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of global functioning evolution
C-SSRS (suicidal ideation)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of global functioning evolution
QIDS-SR (depression)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of global functioning evolution
GAD-7 (anxiety)
Time frame: Weeks 1, 4, 8, and Month 3
Evaluation of global functioning evolution
CGI (clinical global impression)
Time frame: Weeks 1, 4, 8, and Month 3
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.
Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 31 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →